Compare GBX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | DMRA |
|---|---|---|
| Founded | 1974 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | GBX | DMRA |
|---|---|---|
| Price | $46.00 | $29.57 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $49.00 | $43.00 |
| AVG Volume (30 Days) | 401.9K | ★ 424.5K |
| Earning Date | 04-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 28.02 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $3,240,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.74 | N/A |
| P/E Ratio | $21.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.23 | $16.50 |
| 52 Week High | $59.19 | $34.89 |
| Indicator | GBX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 53.06 |
| Support Level | $45.43 | $27.23 |
| Resistance Level | $48.66 | $34.89 |
| Average True Range (ATR) | 1.48 | 1.94 |
| MACD | -0.50 | -0.21 |
| Stochastic Oscillator | 3.85 | 28.85 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.